ADO

8.70%

2.1¢ anteotech ltd

EuGeni, page-1042

First 1042 Last

Share
Profile

Follow
RandomGuy01

2,473 Posts.

990

17/08/21

00:19

Post #: 55337520
Share

Originally posted by herro: ↑

1. If as has been suggested, Respond Global are likely to initially utilise the BioAccess CareStart RAT in it’s Australian rollout, I think that’s not all bad news for the future prospects of the Eugenie package in this country.

Here’s a link to an large independent study of the BioAccess device conducted in the U.S. earlier this year.
https://www.medrxiv.org/content/10.1101/2021.03.07.21253101v1

In my opinion, Anteo’s Doherty trial results; 97.3% sensitivity, 99.6% specificity, and impressive PCR cycle threshold (Ct) data, compare very favourably with the BioAccess trial results.

Subject to TGA, Anteo’s Australian distributor, Adacus dx have a good basis to commence negotiations in my view.

2. I’ve been trying to understand the challenges Anteo face in overseas markets. There’s a total of 92 countries in Europe and Asia. That’s a lot of regulatory red tape to negotiate. I thought I’d look at just one, Germany.

The Paul-Ehrlich Institute (PEI) is an agency of the German Federal Ministry of Health, with similar credibility imo but broader influence than the Doherty Institute here in Australia.

With several other well credentialed European institutions, the PEI periodically conducts a “comparative evaluation of the sensitivities of SARS-Cov-2 antigen rapid tests”, (or POCTs).

The POCTs are evaluated using the same method and sample source, so unlike some other reviews, the results have both independence and comparability. (Note, specificity is not assessed)

Based on these results, the PEI periodically publishes a list of “state of the art” POCTs. The current list, published on July 12^th is in this link.
https://www.pei.de/SharedDocs/Downl...iew-04-12-2020.pdf?__blob=publicationFile&v=3

My understanding is that in order to be tested in this way, a POCT must first be accredited by Germany’s Federal Institute for Drugs and Medical Devices, (BfArM).

However according to the document (which loses a little in translation): “ …. this comparative evaluation can only cover a random sample of the SARS-CoV-2 tests listed by the BfArM, thus eligible for refunding, and that few other products could not (yet) be taken into account, despite the interests on the part of the manufacturers/distributors.”

So while the CE mark was an important step, imo it's doubtful that sales to any German Government agency would occur without first also obtaining BfArM accreditation and positive analysis from the PEI.

If Anteo’s European/Asian reps/distributors are worth their salt, I’d hope they’re fast tracking the paperwork in each jurisdiction and distributing trial cassettes and readers as their first priority.

3. For what it’s worth, if I was an overseas buyer, I’d think twice about purchasing a product that wasn’t approved in its country of origin. So if anything positive could possibly come from this Delta outbreak, fast tracking from the TGA would be a good start.

One man’s opinion.
Herro

Expand

https://www.dimdi.de/dynamic/de/medizinprodukte/datenbankrecherche/corona-tests-tabelle/

We're already registered in Germany

ADO Price at posting: 18.5¢ Sentiment: Buy Disclosure: Held
30 Upvote

0 Great analysis

Reply

Top Stories

ACW

Actinogen Medical ramps up Alzheimer’s treatment trials, targeting fast-track global approvals

Week 40 Wrap: China's nonsensical stimmy hype wanes (shocking!); HotCopper's picks; oil & inflation

SLS

Solstice Minerals to ramp up drilling campaign at Yarri Gold Project

NTI

Neurotech knocked back by FDA as agency declares target condition not rare enough for special status

WCN

White Cliff jumps 24% on 'bonanza grade' copper rock chips at Rae project, Canada

BCI

BCI reaches close of funding facility for salt-first part of Mardie project

CKA

Cokal upgrades infrastructure for BBM ramp-up in Indonesia

COD

Coda Minerals (ASX:COD) enters rights issue to further exploration in South Australia

BUX

Buxton projects new graphite province discovery at WA Narryer play

RCE

Recce eyes Indonesia for novel anti-infective as Indo-Aus ties grow stronger

There are more pages in this discussion • 1,624 more messages in this thread...

First 1042 Last

Add ADO (ASX) to my watchlist

(20min delay)
Last 2.1¢		Change -0.002(8.70%)		Mkt cap ! $52.28M

Open	High	Low	Value	Volume
2.2¢	2.2¢	2.1¢	$20.83K	964.6K

Buyers (Bids)

No.	Vol.	Price($)
4	2247357	2.1¢

Sellers (Offers)

Price($)	Vol.	No.
2.2¢	164375	3

View Market Depth

No.	Vol.	Price($)
4	2247357	0.021
9	1445497	0.020
10	2127381	0.019
5	1657002	0.018
3	1564748	0.017

Price($)	Vol.	No.
0.022	164375	3
0.023	642868	9
0.024	741966	3
0.025	578846	8
0.026	83915	2

Last trade - 16.10pm 04/10/2024 (20 minute delay)

ADO (ASX) Chart

EuGeni, page-1042

Actinogen Medical ramps up Alzheimer’s treatment trials, targeting fast-track global approvals

Week 40 Wrap: China's nonsensical stimmy hype wanes (shocking!); HotCopper's picks; oil & inflation

Solstice Minerals to ramp up drilling campaign at Yarri Gold Project

Neurotech knocked back by FDA as agency declares target condition not rare enough for special status

White Cliff jumps 24% on 'bonanza grade' copper rock chips at Rae project, Canada

BCI reaches close of funding facility for salt-first part of Mardie project

Cokal upgrades infrastructure for BBM ramp-up in Indonesia

Coda Minerals (ASX:COD) enters rights issue to further exploration in South Australia

Buxton projects new graphite province discovery at WA Narryer play

Recce eyes Indonesia for novel anti-infective as Indo-Aus ties grow stronger

Featured News

Buyers (Bids)

Sellers (Offers)

Featured News

EuGeni, page-1042

Top Stories

Actinogen Medical ramps up Alzheimer’s treatment trials, targeting fast-track global approvals

Week 40 Wrap: China's nonsensical stimmy hype wanes (shocking!); HotCopper's picks; oil & inflation

Solstice Minerals to ramp up drilling campaign at Yarri Gold Project

Neurotech knocked back by FDA as agency declares target condition not rare enough for special status

White Cliff jumps 24% on 'bonanza grade' copper rock chips at Rae project, Canada

BCI reaches close of funding facility for salt-first part of Mardie project

Cokal upgrades infrastructure for BBM ramp-up in Indonesia

Coda Minerals (ASX:COD) enters rights issue to further exploration in South Australia

Buxton projects new graphite province discovery at WA Narryer play

Recce eyes Indonesia for novel anti-infective as Indo-Aus ties grow stronger

Featured News

Buyers (Bids)

Sellers (Offers)

Featured News